GICS Sector : Healthcare
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.
Xeris Biopharma reported a strong third quarter, with total product revenue exceeding $74 million, a 40% increase year-over-year. The company's gross margin expanded to 85%, driven by an improved product mix. Adjusted EBITDA for the quarter was $17.4 million, a significant improvement compared to the same period last year. The company's actual EPS loss was narrower than expected, at -$0.01 versus estimates of -$0.03.
Publication Date: Nov -26
RECORLEV remained the primary growth driver, with revenue more than doubling to $37 million, a 109% increase year-over-year. The average number of patients on therapy grew by 108% versus the same period last year. Gvoke delivered another quarter of steady growth, while KEVEYIS outperformed expectations, driven by new patient additions. The company's revenue guidance for the full year was raised to $285 million to $290 million, a 42% increase at the midpoint.
As Xeris Biopharma continues to invest in growth opportunities, it expects some variability in quarterly EPS results going forward. The company remains committed to maintaining positive adjusted EBITDA. According to John Shannon, CEO, "We're investing in more expansion, driven by a market that is ripe for expansion." The company plans to start the XP-8121 trial in the second half of next year, which is expected to drive R&D spend higher in 2027.
Analysts estimate next year's revenue growth at 27.9%. With a current P/S Ratio of 4.79 and EV/EBITDA of 186.12, the market appears to be pricing in significant growth expectations. The company's ROE is 113.91%, indicating strong profitability. However, the Net Debt / EBITDA ratio is 26.77, suggesting a high level of debt relative to EBITDA. As Xeris Biopharma continues to invest in growth opportunities, its valuation multiples will be closely watched to determine if the current price is justified.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Analysts
Nov -25
Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
Nov -06
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say
Nov -06
Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3
Nov -06
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Moderate Buy” by Brokerages
Oct -31
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?
Oct -16
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
Sep -09
Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy
Sep -05
Growing demand for convenient and effective treatments for severe hypoglycemia, periodic paralysis, and Cushing's syndrome, driven by increasing prevalence of these conditions, advancements in biotechnology, and Xeris Biopharma's innovative products, including Gvoke, Keveyis, and Recorlev, which offer improved patient outcomes and convenience.
Xeris Biopharma's royalty fees from licensed products, contract revenue from collaborations, and other income from miscellaneous sources are expected to drive growth. Increasing demand for innovative biopharmaceuticals, strategic partnerships, and expanding product portfolios are key growth drivers.
Gvoke is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
Ogluo is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
Gvoke HypoPen is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
XeriSol is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
Xeris Biopharma Holdings, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing innovative and differentiated products.
Xeris Biopharma Holdings, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to customers' operations, making it difficult for them to negotiate prices.
Xeris Biopharma Holdings, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, suppliers may still have some leverage in negotiations.
The biopharmaceutical industry is highly competitive, and new entrants can easily disrupt the market. Xeris Biopharma Holdings, Inc. must continually innovate and differentiate its products to stay ahead of new competitors.
The biopharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. Xeris Biopharma Holdings, Inc. must be highly competitive in terms of pricing, product offerings, and innovation to maintain its market position.
| Value | |
|---|---|
| Debt Weight | 103.61% |
| Debt Cost | 9.93% |
| Equity Weight | -3.61% |
| Equity Cost | 9.93% |
| WACC | 9.93% |
| Leverage | -2866.81% |
Value: 6.2
Growth: 7.1
Quality: 5.4
Yield: 0.0
Momentum: 10.0
Volatility: 2.7
1-Year Total Return ->
Value: 3.2
Growth: 8.7
Quality: 7.1
Yield: 0.0
Momentum: 2.0
Volatility: 3.0
1-Year Total Return ->
Value: 6.4
Growth: 3.1
Quality: 4.9
Yield: 0.0
Momentum: 6.5
Volatility: 2.0
1-Year Total Return ->
Value: 6.8
Growth: 5.9
Quality: 3.1
Yield: 0.0
Momentum: 5.0
Volatility: 1.3
1-Year Total Return ->
Value: 8.2
Growth: 5.6
Quality: 7.4
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->
Value: 7.7
Growth: 1.6
Quality: 4.6
Yield: 0.0
Momentum: 0.0
Volatility: 2.3
1-Year Total Return ->